Influenza vaccine quadrivalent - China National Biotec Group

Drug Profile

Influenza vaccine quadrivalent - China National Biotec Group

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator China National Biotec Group
  • Developer Changchun Institute of Biological Products; China National Biotec Group
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Dec 2015 Launched for Influenza virus infections (Prevention) in China prior to December 2015
  • 01 Dec 2015 Changchun Institute of Biological Products initiates enrolment in a phase IV trial for Influenza virus infections (In Infants, In children, In adolescents) in China (ChiCTR-PPR-15007470)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top